Prescribing Pattern of Antiemetics and Treatment Outcomes of Chemotherapy-Induced Nausea and Vomiting in Paediatric Cancer Patients at Bugando Medical Centre Mwanza, Tanzania.
Material type:
TextPublisher number: Wurzburg Road 35, Premises, Post Code: 33102 | P. O. Box 1464 Mwanza, Tanzania | Phone: (255) 28-298-3384 | Fax: (255) 28-298-3386 | Email: vc@bugando.ac.tz | Website: www.bugando.ac.tz Language: English Language: Kiswahili Publication details: Mwanza, Tanzania | Catholic University of Health and Allied Sciences [CUHAS-Bugando] | 2024. Description: Includes ReferencesSubject(s): Summary:
Abstract:
"Background: Chemotherapy-induced nausea and vomiting (CINV) is a common side effect of cancer treatment, affecting up to 40% of patients. It can lead to non-adherence and medication discontinuation. It causes malnutrition, electrolyte imbalance, and increased mortality. Antiemetics are prescribed to prevent and treat these effects, with international guidelines categorizing agents based on their emesis risk.
Study objective: To determine the prescribing pattern and treatment outcome of antiemetic medicine used in the treatment of CINV in paediatric cancer patients.
Methodology: This study involved 112 paediatric patients aged from birth to nineteen years attending an oncology clinic, both inpatient and outpatient. A cross-sectional study was used. The study utilized a semi-structured questionnaire gathering demographic and social data obtained from parents and guardians.
Results: The study involved paediatric with mean age (7.93, SD ± 5.33) years, 61(54.46%) where male patients. Ondansetron was most prescribed 93% than the other antiemetics. It was found that despite using antiemetics, the incidence of nausea and vomiting was 61.16%, with (42.86% acute and 18.30% delayed). Most patients had chemotherapy treatment durations ranging from 1 month to 6 years. Most of them were outpatients from urban areas.
Conclusion: Nausea and vomiting continue to be a challenge, even with antiemetic medication. The study indicated that the severity of CINV was relatively moderate compared to pre-antiemetic treatment."
| Item type | Current library | Status | Barcode | |
|---|---|---|---|---|
| UNDERGRADUATE DISSERTATIONS | MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | Not for loan | 20240923091100.0 |
Abstract:
"Background: Chemotherapy-induced nausea and vomiting (CINV) is a common side effect of cancer treatment, affecting up to 40% of patients. It can lead to non-adherence and medication discontinuation. It causes malnutrition, electrolyte imbalance, and increased mortality. Antiemetics are prescribed to prevent and treat these effects, with international guidelines categorizing agents based on their emesis risk.
Study objective: To determine the prescribing pattern and treatment outcome of antiemetic medicine used in the treatment of CINV in paediatric cancer patients.
Methodology: This study involved 112 paediatric patients aged from birth to nineteen years attending an oncology clinic, both inpatient and outpatient. A cross-sectional study was used. The study utilized a semi-structured questionnaire gathering demographic and social data obtained from parents and guardians.
Results: The study involved paediatric with mean age (7.93, SD ± 5.33) years, 61(54.46%) where male patients. Ondansetron was most prescribed 93% than the other antiemetics. It was found that despite using antiemetics, the incidence of nausea and vomiting was 61.16%, with (42.86% acute and 18.30% delayed). Most patients had chemotherapy treatment durations ranging from 1 month to 6 years. Most of them were outpatients from urban areas.
Conclusion: Nausea and vomiting continue to be a challenge, even with antiemetic medication. The study indicated that the severity of CINV was relatively moderate compared to pre-antiemetic treatment."
There are no comments on this title.
Click on an image to view it in the image viewer